Inloggen
E-mail
Wachtwoord
Paswoord weergeven
Bewaren
Bent u uw wachtwoord vergeten?
Gratis lid worden
Registreer
Registreer
Instellingen
Instellingen
Dynamische koersen 
OFFON
  1. Homepagina
  2. Aandelen
  3. BelgiŽ
  4. Euronext Bruxelles
  5. Oxurion NV
  6. Nieuws
  7. Persberichten
    OXUR   BE0003846632

OXURION NV

(OXUR)
Real-time koersen. Real Time Euronext Bruxelles - 26/11 17:29:48
2.035 EUR   +0.74%
25/11Brusselse beurs hoger geopend
AM
22/11BEURS VAN BRUSSEL : Farmasector zet Bel20 in het rood
AM
22/11Verliezen worden groter
AM
OverzichtKoersenGrafiekenNieuwsRatingsAgendaOndernemingFinanciŽnConsensusHerzieningenBeursproducten 
OverzichtAl het nieuwsAndere talenPersberichtenOfficiŽle publicatiesSectornieuwsAnalyse MarketScreener
Communiquťs de presse de la sociťtť OXURION NV
24/11OXURION to Present at the Ophthalmology Day at BTIG
AQ
22/11OXURION NV Secures EUR 10 Million Convertible Bond Financing from Kreos Capital and Po..
AQ
15/11OXURION NV - First Patient Dosed in Part B of Phase 2 KALAHARI Study Evaluating Multipl..
GL
04/11Oxurion NV Announces Initiation of Equity Analyst Coverage by H.C. Wainwright with a &..
AQ
13/10OXURION : Announces First Patient Dosed in its Phase 2 Study Evaluating THR-687 for the tr..
AQ
11/10OXURION : Positive Phase 2 Part A THR-149 data shared at the America Society of Retina Spe..
PU
11/10OXURION : Positive Phase 2 Part A THR-149 data shared at the America Society of Retinal Sp..
PU
11/10OXURION : Positive Phase 2 Part A THR-149 data shared at the America Society of Retinal Sp..
AQ
05/10OXURION : to Present at the Lytham Partners Fall 2021 Investor Conference
AQ
30/09OXURION : Announces Positive Results from Part A of Phase 2 Study Evaluating THR-149 for T..
GL
09/09OXURION : Business & Financial Update – H1 2021
PU
16/08OXURION : Journal of Pharmacokinetics and Pharmacodynamics highlights desirable PK/PD prof..
AQ
05/08OXURION : to Participate in Upcoming Investor Meetings
AQ
07/04OXURION : Publication in 'Progress in Retinal and Eye Research' highlights the potential o..
PU
18/03Oxurion NV Business and Financial Update, FY 2020
AQ
2020OXURION NV Confirms New Patents for THR-687 Issued by European and US Patent Offices
AQ
2020OXURION : Confirms New Patents for THR-687 Issued by European and US Patent Offices
PU
2020OXURION : Confirms New Patents for THR-687 Issued by European and US Patent Offices
AQ
2020OXURION : ONCURIOUS I-O Portfolio Directed at Boosting T Cell Influx and Activity in Solid..
AQ
2020Oxurion NV Business Update, Q3 2020
AQ
2020OXURION : Business Update – Q3 2020
PU
2020OXURION : Business Update – Q3 2020
AQ
2020Oxurion NV appoints Tom Graney, CFA as Chief Financial Officer
AQ
2020OXURION : appoints Tom Graney, CFA as Chief Financial Officer
PU
2020OXURION : appoints Tom Graney, CFA as Chief Financial Officer
AQ
2020Invitation OXURION R&D Investor Day, Virtual 15 October 2020 at 5.30pm CET/ 11.30am ET
AQ
2020OXURION : Invitation OXURION R&D Investor Day – Virtual 15 October 2020 at 5.30pm CE..
PU
2020OXURION : Invitation OXURION R&D Investor Day – Virtual - 15 October 2020 at 5.30pm ..
AQ
2020SAVE THE DATE : Oxurion to host Virtual R&D Investor Day on 15 October 2020
PU
2020SAVE THE DATE : Oxurion to host Virtual R&D Investor Day on 15 October 2020
AQ
2020Oxurion NV to Present New Pre-Clinical Data on THR-687 at EURETINA 2020 Virtual Meeting..
AQ
2020OXURION : to Present New Pre-Clinical Data on THR-687 at EURETINA 2020 Virtual Meeting, Oc..
PU
2020OXURION : to Present New Pre-Clinical Data on THR-687 at EURETINA 2020 Virtual Meeting, Oc..
AQ
2020OXURION : Business Update, H1 2020
AQ
2020OXURION : Business Update - H1 2020
PU
2020OXURION : Business Update - H1 2020
AQ
2020Oxurion NV to Present at H.C. Wainwright & Co 22nd Annual Global Investment Conference
AQ
2020OXURION : Business Update and First Half 2020 Financial Results to be announced on 17 Sept..
AQ
2020OXURION : to Present at H.C. Wainwright & Co 22nd Annual Global Investment Conference
PU
2020OXURION : to Present at H.C. Wainwright & Co 22nd Annual Global Investment Conference
AQ
2020OXURION : Business Update and First Half 2020 Financial Results to be announced on 17 Sept..
PU
2020OXURION : Business Update and First Half 2020 Financial Results to be announced on 17 Sept..
AQ
2020BICYCLE THERAPEUTICS : Announces First Patient Dosed in Oxurion's Phase II Trial Using a N..
AQ
2020Oxurion NV Reports First Patient Dosed in Phase 2 study evaluating THR-149 for treatmen..
AQ
2020OXURION : Investigational Drug Vericiguat Significantly Reduced the Risk of the Oxurion NV..
AQ
2020OXURION : COVID-19 Statement
PU
2020Oxurion NV - Expert Presentation of Positive Topline Data from a Phase 1 Study evaluati..
AQ
2020Oxurion NV - Additional Topline Data from Positive Phase 1 Trial with THR-687 in Patien..
AQ
2020Oxurion NV - Additional Topline Data from Positive Phase 1 Trial with THR-687 in Patien..
AQ
2019OXURION : ONCURIOUS NV Receives Project Grant from VLAIO to Progress its Pipeline of Next ..
GL
2019OXURION : NV - Data from a Phase 1/2 Clinical Study evaluating THR-317 (anti-PlGF) for DME..
GL
2019OXURION NV : Oxurion NV Business Update - Q1 2019
GL
2019OXURION : to Present Further Preclinical Data at 2019 ARVO Meeting
PU
2019OXURION : announces full enrollment in Phase 1 trial evaluating the safety of plasma kalli..
PU
2019OXURION : announces full enrollment of its Phase 2 trial evaluating efficacy and safety of..
PU
2019OXURION : NV announces full enrollment of its Phase 2 trial evaluating efficacy and safety..
GL
2019OXURION : NV to Present Preclinical Evaluation of Plasma Kallikrein Inhibition for DME at ..
GL
2018OXURION : and Beta Therapeutics To Develop New Heparanase Inhibitors for Treatment of dry ..
PU
2018OXURION : November is Diabetic Eye Disease Awareness Month at Prevent Blindness
PU
2018OXURION : Announces the Appointment of Adrienne Graves to its Board of Directors
PU
2018OXURION : to Present at the Upcoming Ophthalmology Innovation Summit and Provide a Clinica..
PU
2018OXURION : Extends Partnership with Retina Global in Support of Bolivian Diabetic Retinopat..
PU
2018OXURION : Business Update – Q3 2018
PU
2018OXURION : NV Business Update - Q3 2018
GL
2018OXURION : nv Enrolls First Patient in Phase 1 Clinical Trial Evaluating THR-687, a Novel P..
GL
2018OXURION : Enrolls First Patient in Phase 2 Clinical Study Evaluating THR-317 (anti-PlGF) f..
GL
2018OXURION : to present further scientific findings supporting therapeutic potential of THR-3..
PU
2018OXURION : NV to present further scientific findings supporting therapeutic potential of TH..
GL
2018OXURION : Announces New Euronext Brussels Stock Ticker “OXUR” and Launch of Ne..
PU
2018OXURION : NV Announces New NYSE Euronext Brussels Stock Ticker "OXUR" and Launch of New We..
GL
2018Oxurion NV Announces New NYSE Euronext Brussels Stock Ticker "OXUR" and Launch of New W..
GL
2018THROMBOGENICS : Business Update - H1 2018
GL
2018THROMBOGENICS : becomes “Oxurion”
PU
2018THROMBOGENICS : becomes "Oxurion"
GL
2018THROMBOGENICS : Regulated Information - Transparency Statement
PU
1  2  3  4Volgende